搜尋結果
Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
CNBC· 1 日前Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-sta ...
DACA Recipients Could Gain H-1B Visas Under New Immigration Policy
Forbes· 2 日前President Joe Biden announced a new immigration policy that could allow DACA recipients greater ...
Sara Duterte to ‘go on the offensive’ after break from Philippines’ Marcos
South China Morning Post· 14 小時前The vice-president is set to pose a significant political challenge to Marcos, with surveys ...
Bon Jovi’s New Album Pushes One Of Their Most Famous Singles Back To The Charts
Forbes· 1 日前Bon Jovi’s latest album Forever gives the band another quick win on the Billboard charts this ...
Experts say Shein's U.S. IPO is all but dead
CNBC· 3 小時前The Shein logo can be seen on a smartphone, while the Chinese online retailer's website is ...
Farage’s Policies Would Crash the Pound, Ex-BOE Official Warns
Bloomberg· 2 小時前The tax and spendin
Bugatti Tourbillon, a $4.1 Million Hybrid Hypercar to Replace the Chiron
Bloomberg· 20 小時前Have a confidential tip for our reporters? A new Bugatti, the Tourbillon, will succeed the Chir ...
Stocks making the biggest moves premarket: Gilead Sciences, Sarepta Therapeutics, Nike and more
CNBC· 3 小時前Shares dipped 2%, adding to losses from Thursday, when Nvidia closed down 3.5%. The decline ...
Council Post: How AI Empowers A United Go-To-Market Team And Drives Revenue
Forbes· 11 小時前Toby Carrington is the Chief Business Officer at Seismic, making go-to-market teams more ...
Council Post: The End Of The Entrepreneur: Steps To Build A Better Future
Forbes· 11 小時前Neil D’Souza is CEO at Makersite, a data-driven technology company that builds digital twins to ...